Suzhou Hengrui Jialisheng Biomedical Technology

Suzhou Hengrui Jialisheng Biomedical Technology is a specialized biotechnology subsidiary of Jiangsu Hengrui Pharmaceuticals focused on the research and development of innovative therapies for metabolic diseases. The company primarily targets chronic conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH) through a diverse pipeline of small molecules and biologics. Key programs include multi-receptor agonists targeting GLP-1, GIP, and glucagon pathways to provide comprehensive metabolic control. Leveraging the extensive R&D infrastructure of its parent company, Hengrui Jialisheng aims to advance next-generation treatments from discovery through late-stage clinical trials. The company is a critical component of Hengrui's broader strategy to dominate the domestic and international metabolic drug markets.